Early-Onset Alopecia May Signal Chemotherapy Response for Ovarian Cancer


Onset of alopecia within the first 3 cycles of chemotherapy was associated with improved survival in ovarian cancer patients who completed 6 cycles of chemo.

Image © Photographee.eu/Shutterstock.com

Onset of alopecia, a common side effect of chemotherapy, within the first 3 cycles of platinum- and taxane-based chemotherapy was associated with improved overall survival (OS) among patients with epithelial ovarian cancer who completed 6 cycles of treatment.

These results, published in the European Journal of Cancer, are taken from a meta-analysis of four prospective phase III trials that included 5,114 patients assigned platinum- and taxane-based chemotherapy for advanced epithelial ovarian cancer.

“This is the first time to reveal an association of alopecia with chemotherapy response rates and survival in patients with advanced epithelial ovarian cancer,” wrote researchers led by Jalid Sehouli, MD, of the department of gynecology at the University of Berlin, Charité, Berlin, Germany.

The researchers noted two limitations of these results. First, only 5% of all the patients and 2.8% of those who completed 6 cycles of therapy did not experience grade 2 alopecia. Second, the studies included in the meta-analysis may have under- or over-reported alopecia.

“Even though our results are important and serve to further enlighten the associations between toxicity and efficacy of cytotoxic chemotherapy, the exact underlying mechanisms and pathways can only be speculative,” Sehouli and colleagues wrote.

In the analysis, the researchers found that 92% of the 5,114 patients had documented alopecia (grade 0, 2.4%; grade 1, 2.9%; grade 2, 94.7%).

Conducting a univariate analysis, the researchers found that patients who had grade 0 or grade 1 alopecia had significantly worse progression-free survival (PFS) and OS compared with those patients who had grade 2 alopecia.

In order to eliminate any bias for having received a lower dose of chemotherapy, the researchers next looked at only those patients who completed 6 or more cycles of treatment (89%). In this analysis, grade of alopecia was no longer significantly associated with survival outcomes. Instead, the researchers found that time of alopecia onset was linked with survival. Specifically, those patients who had grade 2 alopecia by cycle 3 of treatment had significantly longer OS than those who had alopecia onset later (hazard ratio [HR] = 1.25; 95% CI, 1.04-1.50). However, early-onset alopecia was not associated with an improvement in PFS.

“When adjusting for the common clinicopathologic features such as postoperative tumor residuals, histology, and FIGO stage, early-onset-up to cycle 4-grade 2 alopecia appeared to significantly correlate with a more favorable OS,” the researchers wrote. “It needs to be further elucidated whether early-onset alopecia is just a surrogate marker for higher sensitivity to chemotherapy and hence associated with a longer survival or if other unidentified biological pathways are underlying that correlate alopecia with cytotoxicity and survival.”

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Related Content